XERIS BIOPHARMA HOLDINGS, INC. (XERS) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
31/64
2.4 / 5 stars
All 64 Win/Lose results and 56 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinXERS / S&P 36.55% / 15.20% |
WinXERS / S&P 36.33% / 15.00% |
LoseXERS / S&P -52.38% / 50.40% |
| 2026-Q11/3 |
LoseXERS / S&P -26.11% / -4.33% |
WinXERS / S&P 41.47% / 11.30% |
LoseXERS / S&P -123.33% / 27.70% |
| 2025-Q41/3 |
LoseXERS / S&P -3.56% / 2.65% |
WinXERS / S&P 43.72% / 9.00% |
LoseXERS / S&P -100.00% / 13.40% |
| 2025-Q32/3 |
WinXERS / S&P 74.30% / 8.12% |
WinXERS / S&P 42.05% / 4.61% |
LoseXERS / S&P -77.27% / 13.45% |
| 2025-Q21/3 |
LoseXERS / S&P -14.94% / 10.94% |
WinXERS / S&P 35.62% / 4.83% |
LoseXERS / S&P -50.00% / 10.63% |
| 2025-Q12/3 |
WinXERS / S&P 61.95% / -4.27% |
WinXERS / S&P 29.88% / 4.98% |
LoseXERS / S&P -34.78% / 10.57% |
| 2024-Q42/3 |
WinXERS / S&P 18.95% / 2.41% |
WinXERS / S&P 23.89% / 5.25% |
LoseXERS / S&P -13.64% / 6.15% |
| 2024-Q32/3 |
WinXERS / S&P 26.67% / 5.89% |
WinXERS / S&P 22.72% / 5.89% |
LoseXERS / S&P -2.22% / 6.11% |
| 2024-Q21/3 |
LoseXERS / S&P 1.81% / 4.28% |
WinXERS / S&P 35.31% / 5.38% |
LoseXERS / S&P -19.23% / 5.12% |
| 2024-Q11/3 |
LoseXERS / S&P -5.96% / 10.56% |
WinXERS / S&P 41.18% / 5.71% |
LoseXERS / S&P -19.30% / 5.59% |
| 2023-Q42/3 |
WinXERS / S&P 26.34% / 11.69% |
WinXERS / S&P 48.68% / 6.81% |
LoseXERS / S&P -37.14% / 7.78% |
| 2023-Q31/3 |
LoseXERS / S&P -29.01% / -3.27% |
WinXERS / S&P 54.94% / 7.52% |
LoseXERS / S&P -56.73% / -5.03% |
| 2023-Q22/3 |
WinXERS / S&P 60.74% / 8.74% |
WinXERS / S&P 67.87% / 9.50% |
LoseXERS / S&P -59.06% / -8.57% |
| 2023-Q12/3 |
WinXERS / S&P 22.56% / 7.50% |
WinXERS / S&P 91.23% / 10.77% |
LoseXERS / S&P -61.74% / -15.69% |
| 2022-Q41/3 |
LoseXERS / S&P -14.74% / 7.56% |
WinXERS / S&P 122.97% / 11.88% |
LoseXERS / S&P -54.55% / -17.99% |
| 2022-Q32/2 |
WinXERS / S&P 1.30% / -4.88% |
WinXERS / S&P 180.67% / 13.47% |
No dataXERS / S&P / -1.41% |
| 2022-Q21/2 |
LoseXERS / S&P -39.84% / -16.10% |
WinXERS / S&P 138.77% / 13.71% |
No dataXERS / S&P / 11.04% |
| 2022-Q10/1 |
LoseXERS / S&P -12.63% / -4.60% |
No dataXERS / S&P / 15.97% |
No dataXERS / S&P / 42.23% |
| 2021-Q41/1 |
WinXERS / S&P 19.59% / 11.03% |
No dataXERS / S&P / 15.00% |
No dataXERS / S&P / 96.40% |
| 2021-Q30/1 |
LoseXERS / S&P -39.80% / 0.58% |
No dataXERS / S&P / 10.77% |
No dataXERS / S&P / 69.42% |
| 2021-Q20/1 |
LoseXERS / S&P -9.76% / 8.55% |
No dataXERS / S&P / 6.58% |
No dataXERS / S&P / 51.81% |
| 2021-Q10/1 |
LoseXERS / S&P -8.33% / 6.17% |
No dataXERS / S&P / -1.06% |
No dataXERS / S&P / 7.39% |
| 2020-Q40/1 |
LoseXERS / S&P -17.03% / 12.15% |
No dataXERS / S&P / -3.72% |
No dataXERS / S&P / -33.42% |
| 2020-Q31/1 |
WinXERS / S&P 122.93% / 8.93% |
No dataXERS / S&P / -2.04% |
No dataXERS / S&P / -27.10% |
| 2020-Q21/1 |
WinXERS / S&P 36.41% / 20.54% |
No dataXERS / S&P / -0.46% |
No dataXERS / S&P / -27.11% |
| 2020-Q10/1 |
LoseXERS / S&P -72.34% / -19.60% |
No dataXERS / S&P / 3.47% |
No dataXERS / S&P / -14.75% |
| 2019-Q40/1 |
LoseXERS / S&P -28.28% / 9.07% |
No dataXERS / S&P / 5.36% |
No dataXERS / S&P / 2.99% |
| 2019-Q30/1 |
LoseXERS / S&P -14.07% / 1.70% |
No dataXERS / S&P / 5.02% |
No dataXERS / S&P / 0.21% |
| 2019-Q21/1 |
WinXERS / S&P 13.94% / 4.30% |
No dataXERS / S&P / 6.64% |
No dataXERS / S&P / 8.65% |
| 2019-Q10/1 |
LoseXERS / S&P -40.94% / 13.65% |
No dataXERS / S&P / 8.12% |
No dataXERS / S&P / 14.29% |
| 2018-Q41/1 |
WinXERS / S&P -3.30% / -13.52% |
No dataXERS / S&P / 9.05% |
No dataXERS / S&P / 18.23% |
| 2018-Q30/1 |
LoseXERS / S&P -7.38% / 7.71% |
No dataXERS / S&P / 10.21% |
No dataXERS / S&P / 19.06% |
| 2018-Q20/0 |
No dataXERS / S&P / 3.43% |
No dataXERS / S&P / 9.03% |
No dataXERS / S&P / 14.46% |
| 2018-Q10/0 |
No dataXERS / S&P / -0.76% |
No dataXERS / S&P / 7.68% |
No dataXERS / S&P / 12.46% |
| 2017-Q40/0 |
No dataXERS / S&P / 6.64% |
No dataXERS / S&P / 7.03% |
No dataXERS / S&P / 13.82% |
| 2017-Q30/0 |
No dataXERS / S&P / 4.48% |
No dataXERS / S&P / 5.68% |
No dataXERS / S&P / 17.57% |
| 2017-Q20/0 |
No dataXERS / S&P / 3.09% |
No dataXERS / S&P / 4.83% |
No dataXERS / S&P / 17.74% |
| 2017-Q10/0 |
No dataXERS / S&P / 6.07% |
No dataXERS / S&P / 3.67% |
No dataXERS / S&P / 13.32% |
| 2016-Q40/0 |
No dataXERS / S&P / 3.82% |
No dataXERS / S&P / 2.09% |
No dataXERS / S&P / 7.05% |
| 2016-Q30/0 |
No dataXERS / S&P / 3.85% |
No dataXERS / S&P / 0.20% |
No dataXERS / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | XERS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 9.83% | 20.78% |
| Annualized return | 9.83% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | XERS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 207.14% | 83.14% |
| Annualized return | 25.16% | 12.86% |
10Y · 2018-06-21 to 2026-08-27
| Metric | XERS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -57.47% | 319.30% |
| Annualized return | -8.19% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |